Clinical Trial Update: Study of TACE Combined With Lenvatinib to Prevent Postoperative Recurrence in Patients With MVI Positive HCC [Phase 1, Phase 2]

View source ↗

Summary

A combined TACE and Lenvatinib trial in hepatocellular carcinoma with microvascular invasion aims to prevent postoperative recurrence; current status is unknown…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Lenvatinib (lenvatinib)

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: Hepatocellular Carcinoma, Lenvatinib | Phase 1, Phase 2 | Status: UNKNOWN